{
  "nct_id": "NCT46439032",
  "indication": "Type 2 Diabetes",
  "phase": "Phase 1",
  "sample_size": 44,
  "duration_weeks": 6,
  "dropout_rate": 0.04,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "HbA1c reduction"
  ],
  "secondary_endpoints": [
    "Postprandial glucose reduction",
    "Fasting glucose reduction"
  ],
  "outcome_summary": "Benefit-risk profile does not support further development",
  "success": 0,
  "failure_reason": "Pharmacokinetic issues with drug exposure",
  "start_date": "2023-10-25",
  "completion_date": "2023-12-06"
}